ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

07 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Mar 2025 15:00:00 By Nasdaq GlobeNewswire

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

28 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis 

26 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

25 Feb 2025 15:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

24 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

18 Feb 2025 15:35:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Feb 2025 15:00:00 By Nasdaq GlobeNewswire

Arcutis to Present at the Guggenheim SMID Cap Biotech Conference

27 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

12 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jan 2025 15:00:00 By Nasdaq GlobeNewswire

Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

16 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Dec 2024 15:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Promotions on Executive Management Team

03 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

13 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

06 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

24 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

23 Oct 2024 15:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

18 Oct 2024 07:20:14 By Nasdaq GlobeNewswire